🎉NBME Qbank Surprise! 🤩🤩 NBME Step 1 Qbank Mode is here 💥 4000+ NBME Qs • Smart filters • AI tools • Deep analytics 🚀 Join now & boost your Step 1 prep! ⬇️⬇️⬇️⬇️⬇️⬇️⬇️ 🔗 [Sgin up Free account] join NBMEWAY telegarm channel: @NBMECMS

Channel
Kaplan Step 2 CK 2026
@Kaplan_Step_2_CK
On this record: Growth · Engagement · Posts · Polls · Citations · Cite this entry
4,276subscribers
+0 since we began measuring on 6 August 2026
Risers and fallers across the register · movement among entries of 3,162–10,000.
Register entry
| Telegram ID | -1001720995738 |
|---|---|
| Type | Channel |
| Username | @Kaplan_Step_2_CK |
| Created | Between 1 December 2021 and 31 March 2023— estimated from Telegram’s id allocation, not measured. How this range is calculated. |
| First recorded | 6 August 2026 |
| Last confirmed live | 13 August 2026 |
| Measurements held | 3 |
| Confirmed unchanged | 1 time, most recently 13 August 2026 |
| On Telegram | t.me/Kaplan_Step_2_CK |
Growth
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 13 Aug 2026, 10:34 | 4,276 | +1 |
| 7 Aug 2026, 04:38 | 4,275 | -1 |
| 6 Aug 2026, 13:32 | 4,276 | first reading |
Engagement
20 posts held, back to 31 March 2023 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 5 pagesof Telegram’s post history, 20 posts per page.
Nothing published in the last 30 days. ERR and ER are rolling 30-day measures, so there is nothing to compute — we hold 20 posts for this entry, the most recent from 9 May 2026. An engagement rate over an empty window would be a number about nothing.
Recent posts
🎉NBME Qbank Surprise! 🤩🤩 NBME Step 1 Qbank Mode is here 💥 4000+ NBME Qs • Smart filters • AI tools • Deep analytics 🚀 Join now & boost your Step 1 prep! ⬇️⬇️⬇️⬇️⬇️⬇️⬇️ 🔗 [Sgin up Free account] join NBMEWAY telegarm channel: @NBMECMS
🥳 USMLE Recalls is the game changer in your USMLE exam 😎 ✌️Study smarter not harder✌️ 🆘A moment of hesitation may cause u lifetime of regrets🛑 Happy learning to u all🌹 ☎️For details and membership contact: @usmle_recall 👇👇👇👇👇👇👇👇 https://t.me/USMLERECALLS2021/2184
🏪 😇😇🥰🥰 🥰😇🥰🥰🥰😇 NOV 😅😇😅😇 You don't need more resources. You need the Right ones. We built MCAT Way to be the end of the search.. 🧠 From Day 1 to White Coat. 🔓 ⬇️⬇️⬇️⬇️⬇️⬇️⬇️ https://t.me/addlist/4YUjzWlMtTQ1ZGZh …
Channel name was changed to «Kaplan Step 2 CK 2026»
🎉NBME Qbank Surprise! 🤩🤩 NBME Step 1 Qbank Mode is here 💥 4000+ NBME Qs • Smart filters • AI tools • Deep analytics 🚀 Join now & boost your Step 1 prep! ⬇️⬇️⬇️⬇️⬇️⬇️⬇️ 🔗 [Sgin up Free account] join NBMEWAY telegarm channel: @NBMECMS
🥳 USMLE Recalls is the game changer in your USMLE exam 😎 ✌️Study smarter not harder✌️ 🆘A moment of hesitation may cause u lifetime of regrets🛑 Happy learning to u all🌹 ☎️For details and membership contact: @usmle_recall 👇👇👇👇👇👇👇👇 https://t.me/USMLERECALLS2021/2184
🆘Usmle recalls step 1, 2 and 3 🔝90% repeated questions per block😎 👩🎓Tired of memorizing endless facts for the USMLE exam with no results? 🤩It's time to turn your studying into success with USMLE Recalls! 🥰Say goodbye to stress and frustration, and hello to top scores on the USMLE EXAM. 🤓Join the ranks of our satisfied students and take your first step towards your dream residency today with USMLE Recalls. Enroll…
☄️ 2025 USMLE Recalls: Dominate the Exam! ☄️ Your success is our mission. 🙂 No more stress, no more guesswork. Our proven recall strategies will give you the edge you need to crush the USMLE. 👑 Why settle for average when you can be exceptional? With expert guidance and a tailored approach, you’ll be ready to achieve your highest score yet. 🔥Don’t wait—your future is calling. 👋 Take action now and secure your sp…
Which of the following is the most appropriate immediate next step in this patient's pain management?
- A. Heating pad6%
- B. Local glucocorticoid injection17%
- C. Short-acting opioid32%
- D. Substitution of ibuprofen with naproxen17%
- E . Systemic glucocorticoid11%
- F Topical capsaicin4%
- G. Transdermal fentanyl patch12%
Shares as published, totalling 99%. No per-option vote count is published by Telegram, so none is shown.
A 71-year-old man comes to the ·office due to worsening low back pain. The patient is having significant pain with movement that is limiting his activity, as well as nocturnal pain that is disrupting his sleep. He has had no lower extremity weakness or numbness and no bladder or bowel dysfunction. He is taking ibuprofen 3-4 times a day, and it is not controlling his pain. The patient has a history of prostate cancer …
Educational objective: Chemotherapy-induced peripheral neuropathy typically presents as a symmetric, distal, sensory neuropathy that spreads in a stocking-glove pattern. Common causative agents include platinum-based medications (eg, cisplatin}, taxanes (eg, paclitaxel), and Vinca alkaloids (eg, vincristine }.
Showing the 12 most recent of 20 posts we hold for @Kaplan_Step_2_CK. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Polls
The 3 polls we hold for this entry, as Telegram rendered them when we read the post. A poll’s figures keep moving after that, so each one is dated.
Which of the following is the most appropriate immediate next step in this patient's pain management?
- A. Heating pad6%
- B. Local glucocorticoid injection17%
- C. Short-acting opioid32%
- D. Substitution of ibuprofen with naproxen17%
- E . Systemic glucocorticoid11%
- F Topical capsaicin4%
- G. Transdermal fentanyl patch12%
Shares as published, totalling 99%. No per-option vote count is published by Telegram, so none is shown.
Which of the following is the most likely diagnosis?
- A . Anterior cerebral artery occlusion8%
- B. Chemotherapy-induced peripheral neuropathy56%
- C. Diabetic peripheral neuropathy21%
- D. Spinal cord compression11%
- E. Tabes dorsalis from syphilis3%
Shares as published, totalling 99%. No per-option vote count is published by Telegram, so none is shown.
Which of the following is the most likely explanation for this patient's new symptoms?
- A. COMT inhibitor pharmacotherapy14%
- B. Dementia with Lewy bodies21%
- C. Dopamine agonist pharmacotherapy48%
- D. Frontotemporal dementia8%
- E. MAO-B inhibitor pharmacotherapy9%
Shares as published. No per-option vote count is published by Telegram, so none is shown.
Percentages only — there are no per-option vote counts here, because Telegram publishes none.The public post preview gives each option’s share and a single voter total, and nothing else. Multiplying one by the other would produce a per-option tally that looks measured and is not: the shares are rounded to whole numbers before we ever see them. We print what was published and leave the column that does not exist empty.
The shares need not add up to 100.Rounding alone puts many polls at 99 or 101. A poll that allows more than one answer per voter runs well past 100 by design, and several here do. The bars are drawn against a fixed 100% track at each option’s own percentage rather than normalised to the total, so a poll that exceeds it shows that it does instead of being quietly rescaled.
Read from the 20 most recent posts we hold, published 31 March 2023 to 9 May 2026. Telegram labels each poll by kind — an anonymous poll, a quiz, a closed set of final results — and that label is reproduced rather than paraphrased.
Citation-graph rank
Citation-graph rank — 499,671 of 1,350,102entries in the measured graph. A weighted position computed from the forward and mention edges below — republished posts weigh more than named mentions — and recomputed periodically, over the whole graph. Published only as this ordinal position, never as a score: a position is a fact, and a score printed beside one channel’s name would read as a verdict this register does not make. The two counts beneath stay separate for the same reason mentions are never summed with forwards anywhere else on this page — a named-by count costs nothing to manufacture. The top 100 by this measure, or how it is computed.
Forward network
Republished by
Channels on the register that have forwarded this channel's posts into their own feed.
Republishes
Channels on the register whose posts this channel has forwarded.
Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.
Mentions
Names
Channels on the register whose handles appear in this channel's posts.
A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.
Cite this entry
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 13 August 2026 — this entry's latest reading, not the date you are reading this.
“Kaplan Step 2 CK 2026” (@Kaplan_Step_2_CK), 4,276 subscribers as measured 13 August 2026. Telegram Register, tgregister.com/channel/Kaplan_Step_2_CK.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.